LifeTech Scientific Corporation
先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1302)

VOLUNTARY ANNOUNCEMENT

Pre-market Clinical Trial of LAmbre™ Plus Left Atrial Appendage System Obtained Medical Insurance Coverage in the US

This announcement is made by LifeTech Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide the shareholders and potential investors with updated information in relation to the latest business and new product development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on 19 March 2025, a trial ("**Trial**") of the Group's LAmbre™ Plus Left Atrial Appendage Closure System ("**LAmbre™ Plus**" or the "**Device**") obtained medical insurance coverage in the US. The Trial was initiated by the Company, and all patients enrolled will receive medical coverage. The primary objective of the Trial is to demonstrate the safety and efficacy of the LAmbre™ Plus in reducing the risk of thromboembolism in patients with non-valvular atrial fibrillation by randomized comparison with the commercially available transcatheter LAAO control devices.

The Trial is a prospective, multicenter, randomized controlled study which expects to implant the LAmbre™ Plus at a fee at up to 75 investigational sites in the US. The marketing application for the Device will be submitted to the US Food and Drug Administration ("**FDA**") after satisfying certain clinical milestones.

The Device was independently developed by the Company with further structural optimization on the basis of LAmbre™ Left Atrial Appendage Closure System ("**LAmbre™**"). LAmbre™ is an advanced product in the industry in terms of design and technology which has been widely used in almost 40 countries with nearly 40,000 cases in clinical application around the world. This is a major milestone in the process of international development of the Group. The Company is confident that the Device will obtain US market approval from the FDA after completing pre-market clinical research in the US.

As the LAmbre™ Plus is still subject to further approval from the FDA, shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 21 March 2025

As at the date of this announcement, the Board comprises Mr. XIE Yuehui, Mr. LIU Jianxiong and Ms. RUAN Xingmei being executive Directors; Mr. JIANG Feng being non-executive Director; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.